Stock News Update: Armata Pharmaceuticals (NYSE:ARMP)

Armata Pharmaceuticals (NYSE:ARMP) spotted trading -83.58% off 52-week high price. On the other end, the stock has been noted 46.20% away from the low price over the last 52-weeks. The stock changed -0.85% to recent value of $3.15. The stock transacted 9783 shares during most recent day however it has an average volume of 81.53K shares. The company has 2.41M of outstanding shares and 0.14M shares were floated in the market.  

Armata Pharmaceuticals (NYSE American: ARMP) reported the publication of a case study involving a cystic fibrosis patient who was successfully treated for a multidrug-resistant Pseudomonas aeruginosa infection with the Company’s natural phage product, AP-PA01. The paper, entitled “Successful adjunctive use of bacteriophage therapy for treatment of multidrug‑resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient,” appears in the peer-reviewed journal Infection. In addition to its work with AP-PA01, Armata is engineering its Pseudomonas aeruginosa phage to create a new, synthetic phage product, AP-PA02.

“The publication of this successful treatment case study, with an Armata phage administered through our single-patient expanded access program, adds to the impressive and growing body of evidence demonstrating the effectiveness of our phage product candidates, and bacteriophage in general,” said Todd R. Patrick, Chief Executive Officer of Armata. “To solidify our position as a leader in the development of phage-based therapeutics, we are currently working with key opinion leaders to map out an efficient clinical strategy for both our Pseudomonas and Staphylococcus phage product candidates, and plan to file an IND later this year for our Staphylococcus phage candidate.  Treatment of single patients through the expanded access program has been very helpful in demonstrating the promise of phage therapy. However, the reality is that supporting compassionate use cases limits our ability to focus our resources on formal clinical trials required for FDA approval to bring a potential solution to all patients suffering from drug-resistant bacterial infections. With the growing threat of antimicrobial resistance, it is extremely important that we take the necessary steps to perform rigorous clinical trials so we can move toward commercialization of alternatives to traditional antibiotics.”

Mr. Patrick added, “As such, we plan to end our single-patient expanded access program and instead focus on demonstrating phage efficacy through well-powered clinical trials. The work in these two lead programs will pave the way for development of new phage product candidates, natural or synthetic, that address additional unmet medical need and create new opportunities for corporate or government partnerships.”

 Its earnings per share (EPS) expected to touch remained 68.30% for this year. 

 According to the most recent quarter its current ratio was 1.7 that represents company’s ability to meet its current financial obligations. The price moved ahead of -24.30% from the mean of 20 days, -26.22% from mean of 50 days SMA and performed -49.20% from mean of 200 days price. Company’s performance for the week was -11.52%, -23.55% for month and YTD performance remained 9.06%.


Leave a Reply

Your email address will not be published. Required fields are marked *